ZymoGenetics Sees Positive Phase I Cancer Drug Results
Posted on: Wednesday, 24 October 2007, 15:00 CDT
ZymoGenetics has presented positive interim data from the Phase I/II trial of Interleukin 21 in combination with Nexavar in patients with renal cell cancer.
Preliminary data suggests that the combination is well tolerated, with a toxicity profile similar to known toxicities of each agent alone. The combination therapy has also shown promising anti-tumor activity.
ZymoGenetics said that 11 patients have completed at least one six-week treatment course, and 10 of these 11 patients have had measurable disease per RECIST criteria. All 10 have had a decrease in tumor mass as their best response on study, ranging from 18 to 33% per investigator assessment.
Of these, four patients had unconfirmed partial responses, with at least 30% decrease in tumor measurements per investigator assessment and 3 of these are still on treatment. Of the 11 patients who finished the first treatment course, nine continue to receive therapy on study, and two patients discontinued therapy due to disease progression.
Overall, the majority of adverse events and lab abnormalities have been mild to moderate and consistent with the known safety profiles of IL-21 and Nexavar (sorafenib).
Nicole Onetto, senior vice president and chief medical officer of ZymoGenetics, said: "We were very pleased to see that the combination of IL-21 and Nexavar can be safely administered for repeated courses, and that the majority of patients treated to date experience tumor shrinkage. The Phase II part of this trial should allow us to confirm these promising results."
Source: Datamonitor
Related Articles
- Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- ChemGenex's Omacetaxine Demonstrates Activity in CML Patients Who Have Failed Therapy With Multiple Tyrosine Kinase Inhibitors
- Amylin Combination Treatment Found Effective in Obesity Study
- Cyberonics Announces 1,100th Patient Treated With VNS Therapy(Tm) for Treatment-Resistant Depression (TRD) Since FDA Approval
- Over Half of German Population Favor Combined Treatment of Chinese,Western Medicine
- Treatment With ^Sup 177^Lu-DOTATOC of Patients With Relapse of Neuroendocrine Tumors After Treatment With ^Sup 90^Y-DOTATOC
- Clinical Trial for Pancreatic Cancer Opens at Mayo Clinic Using Tumor-Targeted Gene Therapy Vector
- Combined Treatment of Glioblastoma Patients With Locoregional Pre- Targeted ^Sup 90^Y-Biotin Radioimmunotherapy and Temozolomide
- Richland Firm Introduces Promising Isotope for Cancer Treatment; Prostate Cancer Patient Receives New Seed Therapy By IsoRay Medical, Inc. In a Worldwide First for Cesium-131
 |
 |
User Comments (0)
RSS Feeds